Latest updates for Boehringer Ingelheim
Fresh curated links around Boehringer Ingelheim are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- <![CDATA[Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal]]>
- Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset
- Boehringer Wants Generic For Blockbuster Jardiance Blocked
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset
Boehringer Ingelheim has put up 407.5 million euros in biobucks to secure global rights to a first‑in‑class antibody Immunitas Therapeutics is developing for chronic inflammatory a...
Boehringer Wants Generic For Blockbuster Jardiance Blocked
Boehringer Ingelheim has hit an Arizona business with a patent lawsuit in Delaware federal court seeking to stop it from moving forward with a generic version of its diabetes drug...
<![CDATA[Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio]]>
Boehringer, Amgen discard early immunology candidates over lack of clinical potential
Boehringer Ingelheim and Amgen have both canned early-stage immunology candidates after the prospects showed little clinical promise.
Boehringer hands over funding, marketing rights for Click’s digital therapeutic
Boehringer Ingelheim and Click Therapeutics are restructuring their marketing deal for the software-based schizophrenia treatment CT-155, as the German pharma also opens its coffer...
<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio]]>
<![CDATA[Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand St...
<![CDATA[Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-P...
<![CDATA[Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics ]]>
<![CDATA[Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals ]]>
<![CDATA[FDA Extends Priority Review of Leqembi Iqlik Subcutaneous Injection ]]>
Beigene
Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...
Beigene
Beigene Anonymous (not verified) Thu, 04/30/2026 - 14:18 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...
<![CDATA[Eli Lilly Enters $ 2.3 Billion Agreement to Acquire Ajax Therapeutics ]]>
<![CDATA[Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu]]>
<![CDATA[Eli Lilly Enters Three Separate Acquisitions Totaling $3.83 Billion ]]>
<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>
<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics]]>
<![CDATA[Gilead Enters $5 Billion Agreement to Acquire Tubulis ]]>
<![CDATA[FDA Approves Bizengri for Adults with NRG1 Fusion-Positive Cholangiocarcinoma]]>
<![CDATA[Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request ]]>
<![CDATA[Haisco Enters $745 Million Exclusive License Agreement with AbbVie ]]>
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.